US 12,391,720 B2
Salts and polymorphs of cethromycin for the treatment of disease
David Sullivan, Baltimore, MD (US); Amanda Hill, Cambridge (GB); Kate Wittering, Cambridge (GB); Amy Tapper, Boston, MA (US); and Nikola Kaludov, Deale, MD (US)
Assigned to AliquantumRx, Inc., Baltimore, MD (US)
Filed by AliquantumRx, Inc., Baltimore, MD (US)
Filed on May 24, 2023, as Appl. No. 18/322,767.
Application 18/322,767 is a continuation of application No. 17/109,970, filed on Dec. 2, 2020, granted, now 11,697,667.
Claims priority of provisional application 62/942,508, filed on Dec. 2, 2019.
Prior Publication US 2023/0312633 A1, Oct. 5, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07H 17/08 (2006.01); A61K 31/7048 (2006.01); A61K 31/706 (2006.01); A61P 31/04 (2006.01); A61P 33/06 (2006.01)
CPC C07H 17/08 (2013.01) [A61K 31/7048 (2013.01); A61K 31/706 (2013.01); A61P 31/04 (2018.01); A61P 33/06 (2018.01); C07B 2200/13 (2013.01)] 8 Claims
OG exemplary drawing
 
1. A method of treatment of an infectious disease caused by a bacterium comprising the administration of a therapeutically effective amount of a compound of structural Formula I

OG Complex Work Unit Chemistry
wherein:
a is a fractional or whole number between about 0.5 and 3.5, inclusive;
b is a fractional or whole number between about 0 and 10, inclusive; and
M is hydrochloric acid,
wherein the compound is characterized by the presence of four or more XRPD peaks with d-spacings chosen from about 14.1, about 12.9, about 10.1, about 8.8, about 8.5, about 6.5, about 5.5, about 5.1, about 4.8, and about 4.4 Å;
to a patient in need thereof.